Home > Healthcare > Analytical Instruments > Molecular Analysis > Bioanalytical Testing Services Market

Bioanalytical Testing Services Market Analysis

  • Report ID: GMI8443
  • Published Date: Mar 2024
  • Report Format: PDF

Bioanalytical Testing Services Market Analysis

The global market based on molecule type is segmented into small and large. The small segment accounted for majority of market share of 56.1% in 2023 and is expected to dominate throughout the analysis period.

  • The segmental growth is attributed to the advancements in medical science concerning small molecules and the growing demand to address unmet medical needs.
  • Moreover, increasing number of generic drug approvals and patent expirations for branded small molecule drugs, there is a growing demand for bioequivalence studies. Bioanalytical testing services are essential for demonstrating the bioequivalence of generic drugs compared to their branded counterparts, ensuring comparable pharmacokinetic profiles and therapeutic efficacy, thereby augmenting the segmental growth.
Bioanalytical Testing Services Market, By Test Type (2023)

The bioanalytical testing services based on animal type is classified into DMPK testing, biomarker testing, virology testing, serology testing, immunogenicity testing, and other test types. The virology testing segment has been further divided into in-vivo virology testing and in-vitro virology testing. The biomarker testing dominated the market and was valued at USD 2.2 billion by 2032.

  • Biomarker testing plays a crucial role in the bioanalytical testing services across various industries, including pharmaceuticals, biotechnology, CRO, and academic research. Biomarkers are measurable indicators of biological processes, disease states, or responses to therapeutic interventions.
  • Additionally, the segment growth is majorly attributed to early disease detection, accurate diagnosis, and prediction of disease progression that helps clinicians to make informed decisions about patient management and treatment. Thus, demand for biomarker testing is anticipated to grow in upcoming years.

Based on application, the bioanalytical testing services is divided into oncology, neurology, infectious diseases, gastroenterology, cardiology, and other applications. The oncology segment accounted for significant market position and is predicted to reach USD 1.8 billion by 2032.

  • Bioanalytical testing services play a crucial role in oncology that help in supporting research, drug development, clinical trials, and patient care.
  • Also, bioanalytical testing services assess the pharmacodynamic effects of anticancer drugs on tumor cells, tumor microenvironment, and host immune response. Pharmacodynamics studies helps to understand drug mechanisms, evaluate drug efficacy, and optimize therapeutic interventions. Hence, the interplay of these factors collectively contributes to the expansion of this segment.

Based on end-use, the bioanalytical testing services market is segmented into pharmaceutical & biotechnology companies, contract research organizations, research & academic institutes, and other end-users. The pharmaceutical & biotechnology companies segment held a market share of 45.9% in 2023.

  • Pharmaceutical & biotechnology companies are involved in development of cell & gene therapeutics, nanoparticles & polymers, and biologics. These large molecules needs advanced bioanalytical technologies for quality control, characterization, and regulatory approval. Therefore, large molecule bioanalysis plays crucial role in all phases of clinical trials.
  • Pharmaceutical & biotechnology companies perform the clinical trials and rely on bioanalytical tools to generate and interpret the data. Subsequently, increasing the adoption of bioanalytical testing.
North America Bioanalytical Testing Services Market, 2020 – 2032 (USD Billion)

North America bioanalytical testing services market accounted for USD 1.6 billion revenue in 2023 and is anticipated to grow at CAGR of 8.4% between 2024 and 2032.

  • An important factor contributing to market expansion is the increasing investment in the research and development of new drugs by pharmaceutical and biotechnology industries. With increase in R&D activities, the demand for bioanalytical testing services is projected to increase in upcoming years. Additionally, pharmaceutical and biotechnology companies are focusing on expanding their capabilities in biologics development and partnering with CROs and CDMOs with expertise in biopharmaceutical analysis, thereby accelerating the market growth.
  • Additionally, the presence of major market players is expected to propel the growth of the global market in the region.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for bioanalytical testing services was valued at USD 3.8 billion in 2023 and is predicted to reach USD 8.1 billion by 2032, attributed to the increasing volume of ongoing research activities & clinical trials, along with the development of complex therapeutic modalities.

The small molecule segment accounted for major market share of 56.1% in 2023 and is expected to dominate through 2032 attributed to the advancements in medical science concerning small molecules and the growing demand to address unmet medical needs.

North America market for bioanalytical testing services accounted for USD 1.6 billion in 2023 and is anticipated to observe 8.4% CAGR between 2024-2032 owing to the increasing investment in the R&D of new drugs by pharmaceutical and biotechnology companies.

BioAgilytix, Charles River Laboratories, Inc., Eurofins Scientific, Frontage Labs, ICON Plc, Intertek Group Plc, Labcorp Drug Development, Pace Analytical Services LLC, SGS Société Générale de Surveillance SA, Syneos Health, Thermo Fisher Scientific Inc., and WuXi AppTec

Bioanalytical Testing Services Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 266
  • Countries covered: 19
  • Pages: 195
 Download Free Sample